FUNDAMENTALS |
MarketCap: |
182 557 mill
|
EPS: |
3.21
|
P/E: |
32.69
|
Earnings Date: |
Jul 18, 2024 |
SharesOutstanding: |
1 739.63 mill
|
Avg Daily Volume: |
5.60 mill
|
RATING
2024-05-08 |
A+
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Buy
|
|
Return On Equity: |
Buy
|
|
Return On Asset: |
Buy
|
|
DE: |
Buy
|
|
P/E: |
Strong Buy
|
|
Price To Book: |
Buy
|
|
QUARTER GROWTHS |
|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | n/a | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
2.12x
|
Company: PE 32.69 | sector: PE 15.43
|
PE RATIO: COMPANY / INDUSTRY |
0.37x
|
Company: PE 32.69 | industry: PE 87.83
|
DISCOUNTED CASH FLOW VALUE |
$113.06
(7.74%)
$8.12
|
Date: 2024-05-09
|
Expected Trading Range (DAY) |
$ 102.71 - 107.17
( +/- 2.13%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-05-07 | Earnhardt Lisa D | Sell | 22 852 | Common shares without par value |
2024-04-26 | Stratton John G | Buy | 1 866 | Common shares without par value |
2024-04-26 | Starks Daniel J | Buy | 1 866 | Common shares without par value |
2024-04-26 | Starks Daniel J | Buy | 5 277 | Option (right to buy) |
2024-04-26 | Roman Michael F | Buy | 1 866 | Common shares without par value |
INSIDER POWER |
52.64
|
Last
99 transactions |
Buy:
1 139 195 | Sell:
408 568 |
Forecast:
16:00 - $104.93
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $104.93
Forecast 2: 16:00 - $104.93
Forecast 3: 16:00 - $104.93
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$104.94 (-1.16% )
|
Volume |
6.15 mill
|
Avg. Vol. |
5.60 mill
|
% of Avg. Vol |
109.86 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For ABT
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.